XML 169 R86.htm IDEA: XBRL DOCUMENT
v3.20.4

Segmentation of key figures (Details 10) - USD ($) $ in Millions | 12 Months Ended
--- | ---
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 48,659 | $ 47,445 | $ 44,751
Change to prior year-end [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales, change in % | 3.00% | 6.00% |
Sandoz [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales, change in % | (1.00%) | (1.00%) |
Sandoz [member] | Change to prior year-end [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales, change in % | (1.00%) | (1.00%) |
Sandoz [member] | Retail Generics [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 7,244 | $ 7,590 | 7,880
Net sales, change in % | (5.00%) | (4.00%) |
Sandoz [member] | Biopharmaceuticals [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 1,928 | $ 1,607 | 1,436
Net sales, change in % | 20.00% | 12.00% |
Sandoz [member] | Anti Infectives [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 474 | $ 534 | 543
Net sales, change in % | (11.00%) | (2.00%) |
Sandoz [member] | Anti Infectives [member] | Anti Infectives sold under Sandoz name [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 694 | $ 784 | 826
Operating segments [member] | Sandoz [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 9,646 | $ 9,731 | $ 9,859

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfOperatingSegmentsLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_RevenueFromSaleOfGoodsThirdParties
Namespace Prefix: | nvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
Namespace Prefix: | nvs_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | nvs_ChangeOverPeriodAxis=nvs_PoPYEChangeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentsAxis=nvs_SandozMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_FranchiseAxis=nvs_RetailGenericsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_FranchiseAxis=nvs_BiopharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_FranchiseAxis=nvs_AntiInfectivesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_ProductPortfolioAxis=nvs_AntiInfectivesSoldUnderSandozNameMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |